Carcinoma of Urinary Tract

1 clinical trials · Condition

Record	Firm	Date
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma (NCT01282463)	Eli Lilly and Company	2011-04-01

Every clearance here is in the API, with alerts when new ones post.